Summary

KEY FINDINGS
The North America dry eye disease market growth is anticipated to progress at a CAGR of 5.20% during the forecast period, 2023-2032. The rising prevalence of dry eye, the increasing demand for dry eye products, the surging healthcare expenditure, and the growing government support are among the key factors set to propel the regional market’s growth.
MARKET INSIGHTS
Canada and the United States are assessed for the North America dry eye disease market growth analysis. As per the article published in 2019 by Barbara Caffery, approximately 6 million Canadian adults are likely to have been diagnosed by dry eye disease. The condition substantially impacts the vision-related quality of life, thereby affecting activities like reading, driving, using mobile phones and computers, as well as watching television.
On the other hand, gels, artificial tear drops, and ointments available over the counter help treat dry eye disease. The approval of Xiidra in Canada has provided patients with a novel option to address both the symptoms and indications of dry eye disease. In 2018, Shire Pharma Canada ULC (Shire Canada) and Shire PLC announced that the twice-daily eye drops solution, Xiidra (lifitegrast ophthalmic solution 5%), has been prescribed for the treatment of the indications and symptoms of dry eye disease in adults. As a result, these factors are expected to fuel the dry eye disease market growth in North America over the forecasting years.
COMPETITIVE INSIGHTS
Some of the leading firms operating in the market are Bausch Health Companies Inc, Santen Pharmaceutical Co Ltd, Abbvie Inc (Allergan PLC), Johnson & Johnson, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation caters to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
2.5. MAJOR MARKET FINDINGS
2.5.1. AIR POLLUTION IS A MAJOR CAUSE OF EYE DISEASES
2.5.2. COVID-19 CONTRIBUTED TO A HIGH NUMBER OF DRY EYE DISEASE CASES
2.5.3. ASIAN RACE IS AT HIGHER RISK OF DEVELOPING DRY EYE DISEASE
2.5.4. EXCESSIVE SCREEN TIME CAN INDUCE DRY EYE SYMPTOMS
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. INTRODUCTION OF NOVEL DIAGNOSTIC TECHNIQUES FOR DRY EYE DISEASE
3.1.2. LAUNCH OF PROMISING PIPELINE PRODUCTS FOR DRY EYE DISEASE
3.1.3. GROWING INCIDENCE AND PREVALENCE OF DRY EYE AMONG DIFFERENT AGE GROUPS
3.2. KEY RESTRAINTS
3.2.1. RISK OF SIDE EFFECTS
3.2.2. SUBSTITUTE THERAPIES
3.2.3. EXPENSIVE SPECIALTY PRODUCTS AND COMPLEX REIMBURSEMENT SCENARIO
4. KEY ANALYTICS
4.1. PARENT MARKET ANALYSIS
4.2. KEY MARKET TRENDS
4.3. PORTER’S FIVE FORCES ANALYSIS
4.3.1. BUYERS POWER
4.3.2. SUPPLIERS POWER
4.3.3. SUBSTITUTION
4.3.4. NEW ENTRANTS
4.3.5. INDUSTRY RIVALRY
4.4. GROWTH PROSPECT MAPPING
4.5. MARKET MATURITY ANALYSIS
4.6. MARKET CONCENTRATION ANALYSIS
4.7. VALUE CHAIN ANALYSIS
4.7.1. RESEARCH AND DEVELOPMENT
4.7.2. MANUFACTURING
4.7.3. DISTRIBUTORS
4.7.4. POST-SALES MONITORING
5. MARKET BY TYPE
5.1. OTC
5.2. PRESCRIPTION
6. MARKET BY PRODUCT
6.1. ANTI-INFLAMMATORY DRUGS
6.1.1. CYCLOSPORINE
6.1.2. CORTICOSTEROID
6.1.3. OTHER ANTI-INFLAMMATORY DRUGS
6.2. ARTIFICIAL TEARS
6.3. PUNCTAL PLUGS
6.4. SECRETAGOGUES
6.5. OTHER PRODUCTS
7. MARKET BY DISTRIBUTION CHANNEL
7.1. HOSPITAL PHARMACIES
7.2. INDEPENDENT PHARMACIES AND DRUGSTORES
7.3. ONLINE PHARMACIES
8. GEOGRAPHICAL ANALYSIS
8.1. NORTH AMERICA
8.1.1. MARKET SIZE & ESTIMATES
8.1.2. NORTH AMERICA DRY EYE DISEASE MARKET DRIVERS
8.1.3. NORTH AMERICA DRY EYE DISEASE MARKET CHALLENGES
8.1.4. NORTH AMERICA DRY EYE DISEASE MARKET REGULATORY FRAMEWORK
8.1.5. KEY PLAYERS IN NORTH AMERICA DRY EYE DISEASE MARKET
8.1.6. COUNTRY ANALYSIS
8.1.6.1. UNITED STATES
8.1.6.1.1. UNITED STATES DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
8.1.6.2. CANADA
8.1.6.2.1. CANADA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
9. COMPETITIVE LANDSCAPE
9.1. KEY STRATEGIC DEVELOPMENTS
9.1.1. MERGERS & ACQUISITIONS
9.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
9.1.3. PARTNERSHIPS & AGREEMENTS
9.1.4. BUSINESS EXPANSIONS & DIVESTITURES
9.2. COMPANY PROFILES
9.2.1. AFT PHARMACEUTICALS
9.2.2. ALCON
9.2.3. ALLERGAN PLC (ACQUIRED BY ABBVIE)
9.2.4. BAUSCH HEALTH COMPANIES INC
9.2.5. JOHNSON & JOHNSON
9.2.6. LUMENIS
9.2.7. NOVALIQ GMBH
9.2.8. NOVARTIS AG
9.2.9. OASIS MEDICAL
9.2.10. OTSUKA PHARMACEUTICAL CO LTD
9.2.11. SANTEN PHARMACEUTICAL CO LTD
9.2.12. SENTISS PHARMA PRIVATE LIMITED
9.2.13. SUN PHARMACEUTICAL INDUSTRIES LTD
9.2.14. TEVA PHARMACEUTICAL INDUSTRIES LTD
9.2.15. VISUFARMA